Articles

A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801

Fred Hutchinson Cancer Research Center, Seattle, WA
Medical College of Wisconsin, Milwaukee, WI
Fred Hutchinson Cancer Research Center, Seattle, WA
University of Minnesota, Minneapolis, MN
Stanford Hospital and Clinics, Stanford, CA
University of Alabama at Birmingham, AL
Vanderbilt University School of Medicine, Nashville, TN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Duke University Medical Center, Durham, NC
University of Texas MD Anderson Cancer Center, Houston, TX
The University of Kansas Medical Center, Kansas City, KS
Emory University School of Medicine, Atlanta, GA
The Emmes Corporation, Rockville, MD
The Emmes Corporation, Rockville, MD
The Emmes Corporation, Rockville, MD
University of Minnesota, Minneapolis, MN
The Emmes Corporation, Rockville, MD
Oregon Health and Sciences University, Portland, OR
Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD
Dana Farber Cancer Institute, Boston, MA, USA
Medical College of Wisconsin, Milwaukee, WI
University of Minnesota, Minneapolis, MN
Vol. 103 No. 11 (2018): November, 2018 https://doi.org/10.3324/haematol.2018.195123